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Abstract. Congenital myasthenic syndromes (CMS) form a heterogeneous group of rare diseases characterized by fatigable
muscle weakness. They are genetically-inherited and caused by defective synaptic transmission at the cholinergic neuromus-
cular junction (NMJ). The number of genes known to cause CMS when mutated is currently 30, and the relationship between
fatigable muscle weakness and defective functions is quite well-understood for many of them. However, some of the most
recent discoveries in individuals with CMS challenge our knowledge of the NMJ, where the basis of the pathology has mostly
been investigated in animal models. Frontier forms between CMS and congenital myopathy, which have been genetically
and clinically identified, underline the poorly understood interplay between the synaptic and extrasynaptic molecules in
the neuromuscular system. In addition, precise electrophysiological and histopathological investigations of individuals with
CMS suggest an important role of NMJ plasticity in the response to CMS pathogenesis. While efficient drug-based treat-
ments are already available to improve neuromuscular transmission for most forms of CMS, others, as well as neurological
and muscular comorbidities, remain resistant. Taken together, the available pathological data point to physiological issues
which remain to be understood in order to achieve precision medicine with efficient therapeutics for all individuals suffering
from CMS.
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Congenital myasthenic syndromes (CMS) form a
heterogeneous group of rare diseases that are, by def-
inition, genetically-inherited and primarily caused by
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defective neurotransmission at the peripheral cholin-
ergic synapse known as the neuromuscular junction
(NMJ). Clinical diagnosis of CMS is confirmed
by electromyographic investigations (EMG) with a
decrement of the compound muscle action potential
(CMAP) in response to repetitive nerve stimulation
(RNS) at low (usually 3 Hz) frequency. However,
this decrement is often not systematically recorded,
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mainly because of the fluctuating nature of CMS
symptoms, and gene sequencing for clinical pur-
pose is now a gold standard for ascertaining the
diagnosis.
The use of reverse genetics to identify the genes
which cause CMS has greatly improved our basic
knowledge of the NMJ the last 20 years. The first
mutation causing CMS was identified by a candidate
gene approach in the CHRNE gene, which encodes
the -subunit of the pentameric acetylcholine recep-
tor (AChR) [7]. The number of known causative
genes is now 30, with mutation frequencies ranging
from extremely low (private gene with one sin-
gle individual reported in the literature) to a high
value (up to 42 % for CHRNE), and the relationship
between fatigable muscle weakness and defective
functions are quite well-understood for many of them
[8]. This knowledge led to the use of drug-based
treatments, aimed at improving neuromuscular trans-
mission, which are frequently effective in reducing
fatigable muscle weakness. Excellent reviews of the
current knowledge of the clinical features, genetics,
pathophysiology and drug-based treatment of CMS
have recently been published elsewhere, and we rec-
ommend them to the reader [9–12].
In this review, we would like to focus on some
of the most recent discoveries concerning CMS in
humans which challenge our knowledge of the NMJ.
First, we consider forms of CMS with unexpected
comorbidities, where the basis of the pathology has
mostly been investigated in animal models. We also
discuss frontier forms with congenital myopathy
(CM) with all the associated diagnosis complexity
that these forms represent for the clinician and for
the management of the disease. Next, we discuss
some possible implications of the findings of electro-
physiological and histopathological investigations on
individuals with newly identified forms of CMS and
how they may reflect the role of functional plastic-
ity of the NMJ in the response to CMS pathogenesis.
Finally, we address some of the issues remaining to
be resolved in order to propose efficient treatment and
achieve precision medicine for all the individuals suf-
fering from this highly heterogeneous group of rare
diseases.
CMS, COMORBIDITIES AND
NEUROMUSCULAR FRONTIER FORMS
During the last four years, there has been an
impressive increase in the number of identified genes
known to cause rare diseases, including CMS, with
the systematic use of whole exome sequencing tech-
nology in genetically-undiagnosed individuals. The
genes causing CMS encode both proteins that are crit-
ical for the NMJ as well as other proteins with still
unknown synaptic functions (Fig. 1, Table 1). Most
of the reported mutations are recessively inherited,
with the exception of those observed in SYT2 [13],
SNAP25 [14] and in the genes encoding the AChR
subunits resulting in the slow channel form of CMS
(SCCMS) [15]. No X-linked form of CMS has been
reported so far. Some recently identified causal genes
are linked to forms of CMS with neurological or mus-
cular comorbidities which are direct results of the
gene defect but are not improved by the treatments
commonly used to treat defective neuromuscular
transmission (Table 2).
Neurological comorbidities
Two years ago, only one form of presynaptic CMS
had been identified, linked to loss-of-function muta-
tions in the gene encoding the presynaptic choline
acetyltransferase enzyme ChAT (Fig. 1). The num-
ber of presynaptic forms of CMS is now 7, with
an extremely low frequency of occurrence in all
of them which, with the exception of CHAT and
SLC5A7 related forms (Table 1), have only been
reported in isolated individuals. SLC5A7 encodes
the hemicholinium sensitive-high-affinity choline
transporter 1 (CHT1), expressed by all choliner-
gic neurons, which imports choline, generated by
hydrolysis of ACh by acetylcholinesterase (AChE),
from the synaptic cleft into the nerve terminal
(Fig. 1). One dominant-negative frameshift mutation
in this gene has been reported to cause hereditary
motor neuropathy [16]. On the other hand, loss-
of-function mutations (missense and nonsense) in
SLC5A7 cause CMS with episodic apnea (EA) dur-
ing early infancy (CMS-EA), as do loss-of-function
mutations in CHAT [17]. A third gene recently
shown to cause CMS-EA is SLC18A3, which encodes
the vesicular ACh transporter (VAChT) required for
uptake of newly synthesized ACh into presynaptic
vesicles [18, 19].
These three presynaptic proteins, critical for
cholinergic metabolism, are expressed in all cholin-
ergic neurons. It is well known that nicotinic
cholinergic neurotransmission plays an important
role in “higher-level” functions such as behavior and
cognition [20]. Reflecting this role, five of the eight
infants with CMS-EA due to SLC5A7 or SLC18A3
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Fig. 1. presynaptic CMS causal genes and related proteins recently identified as causing CMS when mutated. Schematic representation of
one NMJ with the pre- (nerve terminal) and post-synaptic (muscle fiber) compartments separated by the synaptic cleft containing a specific
basal lamina. The terminal Schwann cells are not represented for clarity. The causal genes (written in italics and in brackets) resulting in
presynaptic forms of CMS encode proteins involved in cholinergic metabolism (CHT1, ChAT, VAChT) or synaptic vesicles docking and
release. Uptake by the nerve terminal of choline resulting from hydrolysis of acetylcholine (ACh) by AChE from the synaptic cleft is assumed
by CHT1. ChAT will use choline to synthesize new molecules of ACh that will be collected into synaptic vesicles by VAChT. Synaptic
vesicles filled with ACh are docked to the nerve terminal membrane close to the synaptic cleft by SNARE proteins including synaptobrevin-1,
synaptotagomin-2 and SNAP-25. Munc13-1 helps the maturation of synaptic vesicles by acting in their priming prior to vesicle fusion and
participates in the activity-dependent refilling of readily releasable vesicle pool (RRP). The basal lamina laminin 5 protein would interact
with the synaptic vesicle protein SV2A to favor the vesicular exocytosis. Agrin would have a presynaptic impact, either directly or through
a retrograde signaling pathway, which remains to be better characterized.
mutations suffer from severe cognitive impairment
(Table 2). Whether this comorbidity results from
episodes of brain hypoxia during EA, or is a direct
consequence of defective central cholinergic neu-
rons, has to be further investigated. Sudden apneic
episodes are one of the most severe clinical fea-
tures of CMS. They have sometimes been reported
in CMS as a result of mutations in genes encoding
subunits of AChR (fast channel syndrome), rapsyn
and the skeletal muscle voltage-gated sodium chan-
nel NaV1.4. However, the systematic association of
EA with loss-of-function in genes encoding neuronal
proteins critical for presynaptic cholinergic home-
ostasis (uptake, local synthesis and vesicular upload
of the neurotransmitter, Table 2) suggests that these
episodes result from the critical role of cholinergic
transmission in respiratory functions during devel-
opment [21, 22].
A further presynaptic group of CMS, due to muta-
tions in genes encoding members of the soluble
N-ethylmaleimide–sensitive factor attachment pro-
tein receptor (SNARE) complex, have also emerged
from high-throughput sequencing of human sam-
ples. This complex drives the docking or fusion
of the synaptic vesicles (SV) with the presynaptic
motoneuronal membrane (Fig. 1). Dominant muta-
tions in SYT2 and SNAP25B genes, encoding the
synaptotagmin 2 and the SNAP25B proteins of
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Table 1
Genes currently known to cause CMS when mutated and function primarily impaired by the mutations
Primary impaired function Protein (Gene symbol)
Presynaptic cholinergic metabolism choline acetyl-transferase (CHAT), high-affinity choline transporter 1
(SLC5A7), vesicular acetylcholine transporter (SLC18A3)
Neuronal ACh release synaptotagmin 2 (SYT2), vesicle-associated membrane protein 1 (VAMP1),
synaptosomal-associated protein 25 (SNAP25), Munc13-1 (UNC13A)
Synaptic anchoring of AChE collagenic tail of AChE (COLQ)
Muscle action potential genesis subunits of AChR, adult isoform (CHRNE, CHRNA1, CHRND, CHRNB1),
skeletal muscle voltage-dependent sodium channel (SCN4A)
Post-synaptic AChR aggregation rapsyn (RAPSN), DOK7 (DOK7), agrin (AGRN), LRP4 (LRP4), MuSK
(MUSK)
Protein glycosylation GFPT1 (GFPT1), DPAGT1 (DPAGT1), GMPPB (GMPPB), ALG2
(ALG2), ALG14 (ALG14)
Presynaptic differentiation or organization laminin 2 (LAMB2), laminin 5 (LAMA5)
Mitochondrial energetic metabolism mitochondrial tricarboxylate transport protein (SLC25A1)
Structural proteins with unknown synaptic function plectin (PLEC), myosin 9A (MYO9A), collagen -1 (XIII) chain
(COL13A1), prolyl endopeptidase-like (PREPL)
Gene symbols are according to the HUGO Gene Nomenclature Committee (HGNC). Genes are classified from the most frequently mutated
to the last frequently mutated for a same impaired function. NMJ = neuromuscular junction; ACh = acetylcholine; AChR = acetylcholine
receptor, DOK7 = dowstream of kinase 7, LRP4 = low-density lipoprotein receptor-related protein 4, MuSK = muscle specific kinase, GFPT1
= Glutamine-fructose-6-phosphate aminotransferase 1, DPAGT1 = UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosamine-
phosphotransferase, GMPPB = Mannose-1-phosphate guanyltransferase beta, ALG2 = alpha-1,3/1,6-mannosyltransferase, ALG14 = UDP-
N-acetylglucosaminyltransferase subunit.
the vesicle-associated (v-SNARE) and presynaptic
membrane-associated (t-SNAREs) complex respec-
tively, were shown to cause CMS without (SYT2)
or with (SNAP25B) neurological comorbidities in
individuals with isolated forms of CMS (cortical
hyperexcitability, cerebellar ataxia, and intellectual
disability, Table 2) [14, 23].
The absence of signs suggesting defective high-
level functions in individuals with SYT2 dominant
mutations may be due to the functional redundancy of
synaptotagmin paralogs and to the restricted expres-
sion of the B isoform of synaptotagmin 2 encoded by
this gene. However, they presented with a Charcot-
Marie Tooth-like clinical pattern in two unrelated
families [13, 23]. In one family, affected members
developed foot deformities in childhood including
pes cavus and hammer toes. In the second family,
congenital hip dislocation was reported in addition to
foot deformities. Neurophysiological study showed
a Lambert-Eaton Myasthenic Syndrome-like pattern
with low-amplitude of CMAP and marked increment
after brief exercise (see below). In addition, a slight
reinnervation pattern on needle electromyography of
distal muscles, consistent with motor neuropathy was
recorded in one family [13]. This CMS-like form
benefited both at the clinical and neurophysiolog-
ical level from treatment with 3,4-diaminopyridine
(DAP), a chemical inhibitor of presynaptic K+
channels.
The clinical association between CMS and neu-
rological disorders due to defective docking or
exocytosis of SV has been further emphasized by
the recent identification of loss-of-function muta-
tions in the genes encoding VAMP1 and Munc13-1
(Fig. 1, Table 2). VAMP1 is a member of the synap-
tobrevin family (v-SNARE). Four individuals with
CMS from two unrelated families, were shown to
possess loss-of-function mutations in VAMP1 [4]. All
presented severe impairment of developmental mile-
stones. Munc13-1 is a partner of syntaxin 1B – a
t-SNARE component – and is critical for the assem-
bly of the SNARE complex, which promotes priming
of the SV in preparation for release in response to
Ca2+ entry [1]. Loss-of-function of UNC13A has
been reported in one patient with CMS, microcephaly
and cortical hyperexcitability that could be related to
the expression of Munc13-1 in glutamatergic neu-
rons [24]. Interestingly, one amino-acid substitution
exerting a gain-of-function effect in Munc13-1 has
subsequently been reported in one isolated individ-
ual with dyskinesia, developmental delay and autism
[25]. The impact of this gain of function mutation on
neuromuscular transmission was not investigated.
The gene most recently identified as harboring
mutations causing CMS with possible primary presy-
naptic dysfunction is LAMA5, which encodes the -5
isoform of laminin, a basal lamina protein [26]. In
vitro analyses showed that the pathogenic amino-
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Table 2
Clinical features of forms of CMS with causative genes recently reported
Gene symbol GMPPB COL13A1 MYO9A LAMA5 SLC5A7 SLC18A3 VAMP1 SYT2 SNAP25 UNC13A
Protein GMPPB collagen -1
(XIII) chain
myosin 9A laminin 5 CHT1 VAChT VAMP1 synaptotagmin
-2
SNAP25 Munc13-1
Reported
families
10 2 2 1 5 3 3 2 1 1
Inheritance AR AR AR AR AR AR AR AD de novo AR
Reported cases 14 3 3 1 5 4 5 11 1 1
Ptosis yes (3) yes (3) yes (3) yes yes (5) yes (2) no (5) slight (2) yes yes
Apnea N.D. N.D. yes (1) no yes (5) yes (1), no (1),
ventila-
tion (2)
no (5) N.D. no N.D.
Cognitive
delay
mild (1) LD (1) yes (1), LD (1) no yes (3) LD (2), yes
(1),
N.D. mild language
delay (1)
yes yes
Response to
AChEI
yes (12/14)a no (2/2) yes (3/3) mild yes (4/5) yes (2/2) yes (5/5) no (2/2) no no
Other
medications
DAP and/or
salbutamol
DAP
+salbutamol
DAP (1), DAP
+FLX (1)b
DAP N.D. DAP
+salbutamol (1)
N.D. DAP (2) DAP DAP
Other specific
features
raised CK
level (10/10)
micrognathia
(3)
N.D. facial tics,
mild volume
loss of brain
N.D. JC (3),
retrognathia
(2), CF (1)
JC (2), joint
laxity (1)
foot
deformities
JC cortical
hyperexci
tability
aThe denominator of the fraction indicates the number of patients who received examination or medication. bCrisis after this combination was reported. AR = autosomal recessive; AD = autosomal
dominant; N.D. = no data, LD = learning difficulties; AChEI = acetylcholinesterase inhibitor; DAP = 3,4-Diaminopyridine; FLX = fluoxetine; JC = joint contractures; CF = mild reduction of left
ventricular cardiac function.
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acid substitution decreased binding of laminin 5 to
the vesicular protein SV2, and impaired neural cell-
adhesion and extension of cell projections. Whether
this isoform of laminin is expressed in the central
nervous system is unknown, and the individual with
the LAMA5 loss-of-function mutation suffered from
myopia and facial tics but no intellectual disability. As
emphasized above, most of these presynaptic forms
are observed at a very low frequency. This could be
due to undiagnosed individuals suffering from forms
of CMS masked by most prominent neurological
signs.
Muscular comorbidities
The clinical presentations of CMS are highly
variable, and one well-known differential diagnosis
of CMS is congenital disorders of skeletal mus-
cles, including the congenital myopathies (CM)
and the congenital muscular dystrophies and their
later onset limb-girdle muscular dystrophy (LGMD)
forms. What was already a complex picture has
recently become even more challenging with new
clinical presentations that confound standard anatom-
ical classifications. Atypical phenotypes associated
with classical CMS genes resembling other types of
neuromuscular diseases (LGMD, distal myopathies)
have been observed. Conversely, significant fatigue
and a positive response to AChE inhibitors have
been reported in individuals with CM/CMD diag-
nosed at the molecular level. This striking overlap
may be explained by the fact that numerous molecules
involved in NMJ formation, maintenance and func-
tioning are expressed in other regions of the muscle
fiber, playing critical roles in key cell functions
such as membrane trafficking, nucleus migration, or
sarcolemma stability.
Some forms of CMS mimic specific types of CM
and CMD/LGMD
GMPPB encodes a GDP-mannose pyrophospho-
rylase that catalyzes the synthesis of GDP-mannose,
a sugar nucleotide essential for both N- and O-
glycosylation of proteins. GMPPB mutations were
first reported to cause LGMD without any clinical
evidence of synaptopathy [27]. Two years later, loss-
of-function mutations of GMPPB were identified in
11 individuals suffering from CMS [28]. All had ele-
vated CK levels and muscle level of -dystroglycan
was decreased. Age at presentation was from 1.5
to 31 years. Four individuals were first diagnosed
as suffering from LGMD. An episode of general-
ized sudden weakness and fluctuations of muscle
strength was reported in one individual and fatiga-
bility during effort in another one. All individuals
had CMAP decrement in response to nerve stimula-
tion and benefited from the use of AChE inhibitors
(prostigmin or pyridostigmin) as did most of the
individuals with CMS. Additional individuals suf-
fering from overlapping forms of LGMD and CMS
due to loss-of-function mutations in GMPPB have
been described since this first report, strengthening
the inclusion of the GMPPB-linked form of CMS
in the emerging group of CM with synaptopathy
or CMS with myopathy [29–31]. The first member
of this group is probably Fukuyama-type congenital
muscular dystrophy (FCMD) since aberrant neu-
romuscular junctions were also observed in this
secondary alpha-dystroglycanopathy due to muta-
tions in the gene encoding fukutin [32]. The latter
group may also include the limb-girdle form of CMS
with tubular aggregates resulting from mutations
in GFPT1, which encodes glutamine-fructose-6-
phosphate transaminase 1, another enzyme critical
for protein glycosylation. A recently published long-
term follow-up of 11 individuals stressed a clinical
evolution toward myopathic weakness that occurred
concomitantly to ineffectiveness of usual CMS treat-
ments [33].
Five individuals from three unrelated families were
reported with a recessively-inherited form of CMS
due to mutations in the gene encoding agrin, a basal
lamina protein whose neural isoform is well known
to play a key role in NMJ formation and mainte-
nance by triggering post-synaptic AChR clustering
[34]. All patients displayed CMS with distal muscle
weakness and atrophy reminiscent of distal myopa-
thy [5]. Age at onset was from birth to 15 years. MRI
and neurophysiological studies were compatible with
a mild myopathy restricted to distal limb muscles.
However, CMAP decrement in response to RNS as
well as immunostaining and ultrastructural analyses
of muscle end-plate regions pointed towards neuro-
muscular transmission defect and a diagnosis of CMS
(see below).
Some forms of CM display secondary
neuromuscular transmission defects
Conversely, a series of individuals with CM and
myasthenic features (fatigability, neurophysiological
or histopathological evidence of NMJ remodeling)
have been published in recent years (see [35] for
review). Most were linked to genes causing cen-
tronuclear myopathies (MTM1, BIN1 and DNM2),
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which may be due to the role played by the
related proteins (myotubularin 1, amphiphysin-2 and
dynamin-2, respectively) in membrane trafficking
and recycling which is a key cell process for post-
synaptic AChRs [36–38]. Isolated individuals with
myasthenic features were also reported as having
mutations in the TPM2 and TPM3 genes encoding
tropomyosin 2 and 3, and in RYR1 coding for the
ryanodine receptor [39, 40]. The myasthenic features
suggest that the neuromuscular transmission defect
contributes to muscle weakness in these individu-
als. Accordingly, most were reported to benefit from
treatment with AChE inhibitors and this should be
kept in mind when clinically managing individuals
with CM.
FUNCTIONAL PLASTICITY OF THE NMJ
UNDERLINED BY
NEUROPHYSIOLOGICAL
INVESTIGATION OF CMS
Electrophysiological investigation of the NMJ
Clinical evidence of muscle fatigability resulting
from impaired neuromuscular transmission is mainly
obtained from EMG investigation. Decrement of the
fifth CMAP, in response to 2–5 Hz RNS, by more than
10% of the initial value, is usually taken to confirm the
diagnosis of CMS, in the knowledge that the ampli-
tude of the CMAP in normal individuals changes little
at these frequencies [13]. Because the CMAP reflects
the summed effect of the AP of many muscle fibers,
it may not detect ‘subthreshold’ impairment of trans-
mission at individual NMJs during RNS. By contrast
Single Fiber EMG (SFEMG), which measures the
temporal instability, or ‘jitter’, of the activation of
individual muscle fibers by the nerve, is a highly
sensitive, but unspecific, method that can detect sub-
threshold impaired neurotransmission at even 1-2
NMJs [41].
While these approaches can provide diagnostically
useful evidence of impaired neuromuscular transmis-
sion, they are generally unable to identify which steps
in the complex sequence of events leading to trans-
mission are primarily affected. Detail at this level can
only be obtained by making intracellular recordings
of synaptic events from NMJs in isolated motor point
biopsy samples e.g. [42–44]. Unfortunately, very few
centers world-wide are equipped to do this on human
muscle biopsies, with the result that we remain igno-
rant of the exact nature and site of neurotransmission
impairment in many forms of CMS.
Post-exercise CMAP increment in presynaptic
CMS
In the increasing number of presynaptic forms of
CMS described above, as in virtually all forms of
CMS, significant decrement of the CMAP is observed
during RNS at 2–5 Hz. Two important exceptions to
this rule are CMS caused by mutations in CHAT, in
which there is no decrement at this low frequency in
most of the individuals [2, 3], and in the individual
with CMS related to VAMP1, in whom increment was
observed in response to RNS [4]. Seemingly para-
doxically, in a number of these presynaptic forms,
voluntary exercise (e.g. for 10 s) or nerve stimula-
tion at high frequency (e.g. 20 Hz for 20 seconds
or 10 Hz for 5 min) results in a transient reduc-
tion of this decrement, and may even lead to the
CMAP becoming substantially bigger [4, 5]. To inter-
pret these somewhat confusing findings, it is helpful
to review some basic features of neuromuscular
transmission.
Neuromuscular transmission during repetitive
activity in normal conditions
Nerve impulses (nerve action potentials, or
‘nAPs’) activate muscle fibers by the process of neu-
romuscular transmission [12]. Each nAP opens a
number of CaV2.1 channels in the nerve terminal
allowing an influx of Ca2+. The resulting transient
increase in Ca2+ concentration within the nerve ter-
minal causes the release of a number (20–200 in
vertebrates) of multi-molecular ‘quanta’ of the trans-
mitter, acetylcholine (ACh) into the synaptic cleft.
These quanta correspond to the amount of ACh (about
10,000 molecules) contained in each SV. This release
occurs by exocytosis at specialized structures in the
presynaptic membrane, the ‘active zones’ (AZs). The
action of transmitter on the muscle fiber causes a
transient increase of its resting membrane potential
by about 35–40 mV, the so-called endplate poten-
tial (EPP). The EPP is normally great enough to
cause opening of the voltage-gated sodium channels
(NaV1.4) in the postsynaptic muscle membrane, thus
triggering a mAP and activating contraction. In addi-
tion to this evoked release, transmitter quanta are
also released spontaneously, at random, each one
generating a small (about 1 mV) ‘miniature EPP’
(mEPP).
Most muscles are activated by short bursts, or
longer trains, of nerve impulses at frequencies
between 10–100 Hz [45]. During such activity, the
amplitude of the EPP usually declines. However,
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because substantially more quanta are normally
released than are required to trigger a mAP, the mus-
cle is still effectively activated, i.e. transmission has
a high ‘safety factor’ [46]. Most of the decline of
EPP amplitude results from changes in the number
of transmitter quanta released by each nAP, the so-
called ‘quantal content’ (QC) of the evoked response.
These changes occur over a wide range of time
scales. A number of factors influence the value of
the QC, and hence the amplitude of the EPP, at any
moment. In Fig. 2 we show, very schematically, the
likely relationships between some of the main fac-
tors, and their impact on the EPP and CMAP, in
normal and pathological muscles. We emphasize that
most of the changes in Ca2+ and RRP depicted rep-
resent our best estimate of what occurs rather than
actual observations which, for the most part, have
not been made. Collectively, these various forms of
modulation of QC are often referred to as ‘short-term
synaptic plasticity’ [47].
The Ca2+ that enters following each nAP is sub-
sequently removed by a combination of processes:
binding to soluble buffers, extrusion from the ter-
minal by Ca2+-ATPases or Na+-Ca2+ transporters,
and sequestration by mitochondria and components
of the ER. Each of these processes has a distinc-
tive time course, some requiring seconds [48]. As a
result, during ‘physiological’ activity at frequencies
of 10 Hz and more, there is a gradual build-up of the
basal level of Ca2+ in the terminal (Fig. 2, top row,
Normal). Since the relationship between Ca2+ con-
centration and QC is very non-linear [49], the effect of
the ‘residual’ Ca2+ from previous activity enhances
the effect of the Ca2+ entering during subsequent
nAPs. This potentiating effect would be expected to
cause an increase in the amplitude of the EPP and,
hence, the efficacy of transmission.
In reality, the potentiating effect of Ca2+ build up is
counteracted by a decline in the number of transmitter
quanta capable of being released. These quanta nor-
mally represent only about 0.1% of the SVs present in
the terminal and are considered to represent a distinct
‘pool’ of ‘readily releasable’ quanta, the RRP (Fig. 2,
second row) [45]. Following depletion, the RRP is
only relatively slowly replenished (1–10 seconds)
[45, 50]. The RRP at mammalian NMJs is currently
believed to consist of the 2-3 SVs closely associated
with each AZ, making a total of several hundred SVs
at a typical human NMJ [43, 50]. During low fre-
quency activation (e.g. 0.1–1 Hz), about 5–10% of
the initial RRP is released by each nerve impulse.
During a train of 10 impulses, the RRP would be
reduced to about 60% of its initial value. However,
although the resting rate of RRP replenishment is rel-
atively slow, it speeds up during activity, helping to
maintain adequate release [50].
In clinical practice, these complex interacting
effects on the efficacy of transmission are typically
investigated by stimulating first at 2–5 Hz and then
at 10–20 Hz or by recording CMAPs at 2–5 Hz after
10 s of voluntary activation of muscles.
Neuromuscular transmission in Lambert-Eaton
Myasthenic syndrome (LEMS)
An important and informative example of presy-
naptic transmission impairment is LEMS, an
autoimmune condition in which autoantibodies
directed against CaV channels, located at the AZ,
cause a decline in their number [51, 52]. As a result,
fewer CaV channels open in response to individ-
ual nAPs and so fewer SVs are released during
stimulation at 2–5 Hz, resulting in much smaller,
and often subthreshold, EPPs (Fig. 2, LEMS). As
a result, the amplitude of the CMAP during low
frequency stimulation is much smaller than normal.
During stimulation at 10–20 Hz, as described above,
the cytoplasmic Ca2+ concentration progressively
increases. Because of the reduced quantal release
in LEMS, the RRP initially remains much larger
than at normal NMJs, so the increase in basal Ca2+
leads to a substantial increase in EPP amplitude.
This, in turn, causes the activation of many more
muscle fibers, and an increase in the amplitude of
the CMAP.
Neuromuscular transmission in CMS due to
defective synaptotagmin-2, VAMP1 and
Munc13-1 SNARE proteins
By analogy with LEMS, a post-exercise increment
is generally interpreted as a sign of impaired presy-
naptic function in CMS (Fig. 2, CMS-Pre). Such an
increment has been reported in individuals with CMS
related to synaptotagmin 2 [13, 23], VAMP1 [4] and
Munc13-1 [24], which all play a role in evoked SV
exocytosis. In these conditions, the CMAP during
2–5 Hz stimulation is reduced, though generally not
as much as in LEMS. None of these proteins is known
to have a direct effect on nerve-evoked Ca2+ entry.
This suggests that the post-exercise increment results
primarily from the action of the increase in residual
Ca2+ on a RRP that is larger than normal as a result of
the reduced rate of depletion associated with impaired
SV release.
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Fig. 2. patterns of transmitter release from motor nerve terminals. This figure provides a qualitative view of how different patterns of NMJ
response to repetitive activity (2–5 Hz and 10–20 Hz) may arise, and their impact on the CMAP. Top row, level of Ca2+ in the nerve terminal.
Second row, size of ‘readily releasable pool’ (RRP) of transmitter quanta. Third row, mEPP followed by EPPs. Dotted horizontal line shows
mAP threshold. Bottom row, CMAPs. At normal NMJs, at 2–5 Hz, each nAP causes a brief increase in Ca2+ which triggers release and
generates large EPPs. These all trigger mAPs, so the CMAP shows no decrement. The RRP is almost fully replenished between the responses,
although there may be a little decline. At 10–20 Hz, the individual Ca2+ transients summate, raising the level of Ca2 + . However, now there
is not time for the RRP to be fully replenished between responses, so it declines significantly. The net effect is a modest decline in quantal
content (QC) and EPP amplitude. However, the EPPs remain suprathreshold, so there is no decrement of the CMAP. In LEMS, the individual
Ca2+ transients are much smaller than normal, so the QC at low frequency is very low and few EPPs reach threshold, so the CMAP is greatly
reduced. At higher frequency, the Ca2+ transients summate, so the Ca2+ level increases. At the same time, because the QC is low, there is
little decline of the RRP. As a result, the increased Ca2+ level causes a significant increase in the QC and EPP amplitude, so more EPPs
reach threshold and the CMAP increases. In forms of CMS in which presynaptic function is impaired (for reasons other than a decrease in
Ca2+ entry), QC is reduced at low frequency, even though mEPP amplitude, Ca2+ entry and RRP size are all normal. As a result, there is
little decline in the RRP. At high frequency, the build-up of Ca2+ causes enhanced release and some EPPs reach threshold, causing some
increase in the CMAP. In forms of CMS that act on the postsynaptic membrane, the amplitude of the mEPPs (‘quantal size’) is generally
much smaller than normal. During low frequency activity, although the QC is normal, the EPPs are small and shows some decline. As a
result, many EPPs do not reach threshold so the CMAP is small and may show some decrement as the RRP gets smaller. At high frequency,
the decline in RRP results in a decline in EPP amplitude, in spite of the increase in Ca2+ level, leading to significant decrement of the CMAP.
Neuromuscular transmission in CMS related to
agrin
Particularly intriguing is the incrementing
response reported in some patients with CMS caused
by mutations in the gene encoding agrin [5]. Agrin
induces the post-synaptic clustering of AChRs
through its binding to the Lrp4-MuSK complex
[34]. Patients with agrin mutations have NMJs that
are abnormally fragmented and sometimes show
dispersed postsynaptic gutters with evanescent
borders of AChR staining, resulting in a streaky
pattern of staining [5, 53, 54].
In all these patients with agrin mutations described
so far, there was clear decrement of the CMAP dur-
ing 2–5 Hz stimulation, suggesting low amplitude
EPPs resulting in a critically reduced safety factor
[5, 53, 54]. This is consistent with the pattern
expected for reduced AChRs, as seen classically in
myasthenia gravis and in inherited AChR deficien-
cies (Fig. 2, CMS-Post). However, by contrast with
typical ’postsynaptic’ forms of CMS, a period of
exercise resulted in an increment in CMAP ampli-
tude in each of 5 patients investigated in one study
[5]. This suggests some form of presynaptic abnor-
mality, reminiscent of the CMS-Pre forms described
above.
In searching for an explanation of this intriguing
result, it is of interest that agrin’s binding partner,
Lrp4, also serves as a ‘retrograde’ signal, which
regulates the properties and behavior of the nerve
terminal during synaptogenesis [55, 56] and may
mediate forms of structural plasticity (‘synaptic
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homeostasis’) in the adult [57, 58]. One possibility
is that impaired agrin function somehow interferes
with that retrograde signaling, leading to altered
presynaptic maturation. However, no CMAP poten-
tiation was observed in the few patients with CMS
related to Lrp4, despite a severe impairment of
neurotransmission with reduced quantal content and
EPP amplitude [10].
Post-exercise increment was also reported in the
one individual identified with loss-of-function muta-
tions in LAMA5, which impair interaction of the
basal lamina laminin 5 protein with SV2. SV2 is
a vesicular protein critical for SV fusion with the
presynaptic membrane in response to elevated cyto-
plasmic Ca2+. A dramatic reduction of number of
quanta released was recorded from NMJs in muscle
biopsy samples of this individual [26]. As with agrin,
the details of the pathway leading to impaired neuro-
muscular transmission with post-exercise increment
when laminin 5 is missing remain to be
documented.
It is noteworthy that there is great variation in
the kinetics of the incremental response seen in
these various individuals. In LEMS, the decline
of CMAP potentiation occurs on a time scale of
10–15 seconds [59, 60]. This decline is significantly
slower (2–60 min) in CMS related to synaptotag-
min 2 [13] and agrin [5]. This suggests that quite
different mechanisms are involved in the neurotrans-
mission potentiation observed in these presynaptic
forms of CMS. More detailed clinical neurophysio-
logical studies by EMG in vivo and on isolated biopsy
samples in vitro would help to clarify this situation.
HISTOPATHOLOGICAL INVESTIGATION
OF HUMAN MUSCLE BIOPSY SAMPLES
IN CMS
Overview
The impairment of neuromuscular transmission
that gives rise to the defining features of CMS
is generally accompanied by structural changes in
the cellular components of the NMJ. Because these
are often more easily investigated than the func-
tional defects themselves, they form an important
component of many recent studies of CMS. Immuno-
histological as well as ultrastructural analyses help
to confirm the diagnosis of CMS versus CM and, in
some situations, may point clinicians to a specific
form of CMS.
The mature NMJ is formed by the presynap-
tic nerve terminal of one  motor neuron closely
apposed to the postsynaptic gutters of the skeletal
muscle fiber membrane and ensheathed by several
non-myelinating terminal Schwann cells. Most cur-
rent knowledge of the NMJ in CMS comes from the
investigation of mouse models in which key synaptic
components have been deleted or inactivated. How-
ever, the human NMJ is quite distinct from the rodent
NMJ in at least two aspects. The first concerns its
development. The first steps of synaptic maturation,
including the loss of polyaxonal innervation and the
elaboration of the mature form of the NMJ, occur
postnatally in mice but take place in utero in humans
[61]. The second aspect concerns the architecture of
the adult NMJ. The human NMJ is smaller in diam-
eter (20m vs 30m in mice) and is composed of
smaller and more distinct post-synaptic elements with
an aspect called “cat’s paw” compared to the nice
“pretzel-like form” observed in rodents [43]. In spite
of these differences, morphological investigations of
human samples show many similarities with obser-
vations made in mice, which is critical for developing
precision therapeutics using this species as a preclin-
ical model.
The classical Koelle and Friedenwald histochem-
ical method was one of the first methods used
to visualize the motor endplate by revealing the
synaptic cholinesterase activity [62]. The use of
immuno-histo-fluorescent techniques to label the
innervated zone of myofibers teased from skeletal
muscle biopsies can give a global structural view
of several NMJs by simultaneously staining the
terminal axons (anti-neurofilaments), the Schwann
cells (anti-cytoplasmic S100 glial protein), and the
post-synaptic AChRs (fluorescent −bungarotoxin
conjugates). Ultrastructural analyses complete this
investigation by exploring the fine structure of the
presynaptic, synaptic and postsynaptic elements in a
smaller number of synapses.
Application to CMS
Morphological investigation of the NMJ some-
times suggest a particular form of CMS, and also give
essential cues about the functional plasticity of this
giant cholinergic synapse in pathological situations.
For example, the form of CMS due to loss-of-function
mutations in the gene encoding the ColQ collagenic
tail of the synaptic form of AChE was specifically
recognized by the lack of AChE staining, despite the
presence of nerve terminals and well defined synaptic
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gutters at the NMJ, well before the identification of
the causative gene [63]. Whatever the primary func-
tional impact of the defective protein on the NMJ
may be most, if not all, forms of CMS are eventually
associated with a global dysfunctional organization
due to the complex and dynamic molecular dialogs
occurring between its three cell components [64].
Presynaptic CMS-EA
The global architecture of the NMJ has been inves-
tigated by immunostaining of teased muscle fibers
for only a few patients with a presynaptic form of
CMS. Consistent with the critical role of ACh for
NMJ formation and maintenance, CMS-EA due to
loss-of-function of CHT1 is associated with sev-
eral axons innervating a single NMJ, suggesting
persisting polyaxonal innervation, and a poorly-
differentiated post-synaptic apparatus and generally
defective maintenance of the NMJ, suggestive of
repeated denervation-reinnervation events, as illus-
trated in Fig. 3 [17]. Interestingly, NMJs in this
form of CMS display an increased level of synaptic
butyryl cholinesterase (BChE), whose synaptic func-
tions have not been investigated in detail. This form of
cholinesterase is bound to perisynaptic Schwann cells
and is believed to finely tune synaptic transmission by
regulating the binding of ACh to AChRs located on
these glial cells [65]. How a decrease of CHT1 level
results in increased expression of BChE remains to be
investigated, as does the specificity of this inverse cor-
relation, since the synaptic level of BChE has never
been investigated in muscle samples from individuals
with ChAT or VAChT-related forms of CMS-EA.
Synaptic form of CMS due to agrin dysfunction
As indicated above, some synaptic forms of CMS
linked to mutations in the gene encoding agrin display
distinct features at the clinical as well as neuro-
physiological level. However, this is not related to
specific structural changes of the NMJ. Morpho-
logical investigations of muscle biopsies from one
individual with a clinically unspecific form of CMS
due to AGRN mutations showed profound struc-
tural changes including denervated and remodeled
endplates with a decrease of postsynaptic AChRs,
as expected from the critical role of this synaptic
protein for their aggregation (Fig. 3) [53]. Ultrastruc-
tural analysis confirmed denervation processes and
stressed major presynaptic abnormalities in this indi-
vidual. Similar structural changes were observed in
the agrin-related form of CMS with distal muscle
atrophy and post-exercise increment [5]. In addition,
a less common pattern of postsynaptic gutters with
evanescent borders of AChR staining, resulting in a
postsynaptic streaky staining pattern, was observed
(Fig. 3). This streaky pattern may result from the
presence of secondary synaptic folds which are not
covered by a nerve terminal or perisynaptic Schwann
cells, as observed by electron microscopy, pointing
towards a presynaptic defect.
Post-synaptic CMS with reduced AChR density
The most frequent form of CMS is due to muta-
tions in the CHRNE gene, which result primarily
in reduced post-synaptic nAChR density as seen in
human muscle biopsies [66–68]. Reduced density of
postsynaptic nAChR has also been demonstrated in
muscle biopsies from individuals with CMS due to
mutations affecting other subunits of AChRs [69–71].
Interestingly, in post-synaptic CMS due to mutations
in the gene encoding DOK7, the synaptic morphology
displays specific and major changes in the presy-
naptic compartment with thin nodal axonal sprouts
contacting small separated synaptic cups character-
istics of innervation “en passant” (Fig. 3) [72, 73].
This further underlines the ability of the presynaptic
plasticity of this giant peripheral synapse to compen-
sate for defective neurotransmission, plasticity that
remains to be further understood at the molecular
level since its understanding may open the door to
innovative therapeutics against defective neuromus-
cular transmission whatever its etiology.
TOWARD PRECISION MEDICINE FOR
ALL INDIVIDUALS SUFFERING FROM
CMS
In the near future, the use of high-throughput
sequencing technologies for diagnostic purposes will
be further developed worldwide with national pro-
grams of genomic medicine [74]. Whole-exome or
genome sequencing has been found to be particu-
larly pertinent for CMS, where some years ago, no
causative genes had been recognized for about 50%
of individuals with a clinically-suspected CMS [8].
Even though mutations causing CMS have now been
identified in 30 genes, a huge number of individu-
als suffering from isolated forms of fatigable muscle
weakness still await clinical diagnosis and effective
treatment in clinical referral centers worldwide, and
the undoubtful impact of this clinical uncertainty on
their quality of life deserves further investigation.
Careful neurophysiological investigation of neuro-
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Fig. 3. Morphological changes occurring at the NMJ in some pre- and post-synaptic forms of CMS. Representative whole-mount pictures
of neuromuscular biopsies of individuals with CMS due to mutations in genes encoding presynaptic, synaptic, and postsynaptic proteins.
Dilacerated muscle fibers were used for immunostaining of motor axons using an anti-neurofilament (NF 165 kDa, in green) and for
fluorescent staining of postsynaptic AChRs using tetra-rhodamine-conjugated -bungarotoxin (in red). In one adult control sample, the
terminal axonal branches typically end as a fork innervating a well-defined nAChR structure. Morphological analysis of NMJs from one
young adult suffering from presynaptic CMS related to CHT1 shows a disorganized post-synaptic element with fragmented synaptic gutters
partially innervated by thin terminal axons. An unusual spike-like area pattern of nAChR staining (arrow) contacted by thin terminal axonal
branch was observed in individual with synaptic CMS related to agrin. Strong decrease of axonal branching with innervation “en passant”
contacting small isolated synaptic cups was observed in one adult suffering from post-synaptic CMS related to DOK7. One muscle sample
from one adolescent suffering from congenital myopathy due to an homozygous missense mutation in the STAC3 gene, encoding a component
of the excitation-contraction coupling machinery (6), is shown for comparison with congenital myopathy without evidence for secondary
synaptopathy. In this myopathic condition, the NMJs look nearly normal, with terminal axonal branches contacting well-defined synaptic
gutters. Scale bar = 10m (applies to all pictures).
muscular transmission in several nerve-muscle pairs
during distinct periods of life, as well as histopatho-
logical investigations of muscle biopsy samples and,
wherever possible, electrophysiological studies of
motor point biopsy samples, are mandatory to ascer-
tain the nature of the impairment of neuromuscular
transmission in these individuals so that accurate dif-
ferential diagnoses, excluding alternatives such as
CM or functional somatic syndromes, can be made.
Particular challenges
Many of the most recently identified mutations
causing CMS are ‘private’, known to occur in only 1
or 2 people. In these situations there are major chal-
lenges, both technical and experimental, arising from
the high number of variants existing for each of us and
from the mandatory demonstration of pathogenicity
of the candidate variant when the causative gene to
be searched for has no known physiological rela-
tionship with synapses [75]. Moreover, not only are
most of the remaining individuals with undiagnosed
fatigable muscle weakness sporadic cases, but this
complex trait may have a polygenic origin with
association with susceptibility variants, whose iden-
tification remains challenging in the field of rare
diseases. This challenging situation is a feature of all
forms of orphan diseases, and international programs
of data sharing, such as matchmaker exchange and
RD-connect platforms, have now emerged to favor
emergence of pertinent bioinformatics tools, and to
facilitate transfer of clinical genomic information and
biological samples between research teams to resolve
this critical issue [76, 77].
Therapeutics
Identifying the pathogenic mechanism of each
individual suffering from CMS is also critical to guide
therapy since it is well know that drugs that ben-
efit one form of CMS can be harmful in another
form [10, 11]. From the earliest recognition of CMS
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as a distinct, if heterogeneous, group of conditions,
the main therapeutic tools have been the use of
anticholinesterases [78]. The second main tool has
been the drug 3,4-DAP, which prolongs the nAP by
blocking the neuronal K+ channels whose opening
terminates the nAP [79]. By using these drugs in tan-
dem, it is often possible to use lower doses, resulting
in fewer side effects. However, a number of condi-
tions have been identified in which anticholinesterase
drugs are not only ineffective, but may actually exac-
erbate the symptoms, e.g. inherited AChE deficiency
and ‘slow-channel’ CMS, in which the prolonged
AChR-gated channel openings lead to harmful entry
of Ca2+ into the postsynaptic region and secondary
degeneration of the post-synaptic element [10].
A further new therapeutic dimension, based on
the initially empirical use of sympathomimetics, has
emerged in recent years from efforts to treat patients
whose symptoms are refractory to cholinesterase
inhibitors. Treatment with a range of 2-adrenergic
agonists (ephedrine, albutamol, salbutamol, . . . ) has
proven to be effective in autoimmune myasthenia
as well as in several forms of CMS [10, 11, 35,
80–83]. These drugs, as well as adrenaline itself,
are known to have a variety of short-term (min-
utes) effects on neuromuscular transmission in vitro,
some apparently presynaptic and others postsynap-
tic [84–86]. However, these effects occur only at
concentrations that are an order of magnitude or so
greater than the concentrations attainable in humans
[85, 86]. Furthermore, most of the therapeutic ben-
efits that have been reported for sympathomimetics
in patients with CMS require days, weeks or even
months to be fully achieved, suggesting that these
drugs enhance neuromuscular transmission by induc-
ing long-term structural changes. The mechanism(s)
underlying their effects, or even whether their main
action is on the central or peripheral neurons, the
skeletal muscle, the Schwann cells, or even the vas-
culature, is not known.
The success of sympathomimetics on impaired
neuromuscular transmission has prompted reinves-
tigation of the role of sympathetic innervation of
skeletal muscle. A recent study confirms the asso-
ciation of unmyelinated sympathetic neurons and
NMJs in mouse leg muscles [87]. It further reports
that stimulation of the appropriate sympathetic nerve
activates postsynaptic 2-adrenoceptors and elevates
postsynaptic cAMP production at NMJs. Interest-
ingly, chemical sympathectomy was found to cause
a reduction in NMJ size, AChR density and CMAP
amplitude, and these deleterious effects were largely
reversed by systemic treatment with clenbuterol
for 10 days [87]. These findings seem to demon-
strate significant effects of sympathetic innervation
on the maintenance of NMJs. It will be impor-
tant to learn more about how these effects are
mediated and how they relate to the clinically benefi-
cial effects of sympathomimetics on neuromuscular
transmission.
CONCLUSION
The recent development of sequencing technology
has greatly improved our knowledge of the etiology of
CMS. Despite the increasing power of these molecu-
lar genetic investigations, physiological studies are
ultimately the only way to define the underlying
basis of impaired neuromuscular transmission in the
context of a highly plastic synapse. While EMG
studies in a clinical context can indicate the pres-
ence of impaired neuromuscular transmission, they
cannot define the particular steps in the synaptic
transmission process which are defective following
a developmental or structural defect. Detailed stud-
ies of pathologic NMJs using histological tools and
intracellular recording in motor point biopsies are
the only way such defects can be defined. Whatever
the practical difficulties, such studies remain essen-
tial if the pathogenic mechanisms that give rise to
the various forms of CMS are ever to be understood
and targetable pathways for promoting novel effi-
cient therapies to be identified for muscle weakness
resulting from impaired neuromuscular transmission.
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